| Followers | 8 |
| Posts | 744 |
| Boards Moderated | 0 |
| Alias Born | 07/16/2006 |
Wednesday, August 01, 2007 9:02:58 AM
Brookwood...
Dew, I agree, this acquisition looks good to me on first blush...
See: http://www.brookwoodpharma.com/ for an introduction to Brookwood Pharmaceuticals and its background.
Brookwood was spunout from Southern Research on Jan 19, 2005 to focus upon time-release pharmaceutical formulations. It had developed a commercially injectiable microsphere product while part of Southern Research.
With the spin-off, Brookwood retained its relationship with Carrington’s DelSite subsidiary to develop GelSite, a high molecular weight anionic polysaccharide that provides controlled release of peptides.
Brookwood also has developed a relationship with Genzyme Pharmaceuticals. Genzyme has developed LipoBridge as a delivery technology to facilitate transfer across the blood-brain barrier, and LipoMask to increase circulation half-lives.
On May 7, 2007, Brookwood formed a collaborative joint venture with Targeted Technology Ventures (Aeon Bioscience) to develop new DES technology.
Dew, I agree, this acquisition looks good to me on first blush...
See: http://www.brookwoodpharma.com/ for an introduction to Brookwood Pharmaceuticals and its background.
Brookwood was spunout from Southern Research on Jan 19, 2005 to focus upon time-release pharmaceutical formulations. It had developed a commercially injectiable microsphere product while part of Southern Research.
With the spin-off, Brookwood retained its relationship with Carrington’s DelSite subsidiary to develop GelSite, a high molecular weight anionic polysaccharide that provides controlled release of peptides.
Brookwood also has developed a relationship with Genzyme Pharmaceuticals. Genzyme has developed LipoBridge as a delivery technology to facilitate transfer across the blood-brain barrier, and LipoMask to increase circulation half-lives.
On May 7, 2007, Brookwood formed a collaborative joint venture with Targeted Technology Ventures (Aeon Bioscience) to develop new DES technology.
Recent SRDX News
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/21/2025 05:15:02 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/19/2025 11:16:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/19/2025 11:15:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/19/2025 11:14:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/19/2025 11:13:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/19/2025 11:11:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/19/2025 11:10:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/19/2025 11:08:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/19/2025 11:06:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/19/2025 11:04:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/19/2025 11:03:24 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 11/19/2025 09:48:05 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 11/19/2025 09:32:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/19/2025 09:30:15 PM
- Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities • Edgar (US Regulatory) • 11/19/2025 02:47:33 PM
